Business Context and Reporting Period
This Form 8-K reports on the results of the 2018 Annual Meeting of Shareholders for Arsanis, Inc. (noted as X4 Pharmaceuticals, Inc. in metadata), held on June 5, 2018. The filing details the election of directors and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Proposal 1: Election of Class I Directors
Shareholders elected three nominees to the Board of Directors for terms expiring at the 2021 annual meeting. The voting results were as follows:
- William Clark: 11,767,314 For; 30,631 Withheld; 771,605 Broker Non-Votes.
- David McGirr: 11,767,314 For; 30,631 Withheld; 771,605 Broker Non-Votes.
- Claudio Nessi: 11,587,015 For; 210,930 Withheld; 771,605 Broker Non-Votes.
Proposal 2: Ratification of Independent Auditor
Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- For: 12,569,227
- Against: 282
- Abstain: 41
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each director.
- Confirm the specific responsibilities of the newly elected Class I directors.
- Review the full proxy statement for details on the rationale behind the auditor ratification.
- Note the significant number of broker non-votes (771,605) on the director election proposals.